Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2012, vol. 21, nr 1, January-February, p. 47–53

Publication type: original article

Language: English

Levels of Malondialdehyde, Myeloperoxidase and Nitrotyrosine in Patients with Chronic Viral Hepatitis B and C

Stężenie aldehydu dimalonowego, mieloperoksydazy i nitrotyrozyny u chorych na przewlekłe wirusowe zapalenie wątroby B i C

Emine S. Namıduru1,, Mustafa Namıduru2,, Mehmet Tarakçıoğlu1,, Mustafa Tanrıverdi2,

1 University of Gaziantep, Faculty of Medicine, Department of Biochemistry, Gaziantep, Turkey

2 University of Gaziantep, Faculty of Medicine, Department of Infectious Disease, Gaziantep, Turkey

Abstract

Objectives. Oxidative stress is one of the potential biochemical mechanisms involved in the pathogenesis of chronic viral hepatitis The aim of the present study was to determine levels of oxidative stress in a large group of chronic viral hepatitis (CVH) patients who had not received antiviral treatment, and to assess the relationship between these parameters and viral load, fibrosis score and necro-inflammation of the liver.
Material and Methods. Two hundred CVH patients and 107 healthy subjects were included in this study. Malondialdehyde, myeloperoxidase and nitrotyrosine levels were determined.
Results. Malondialdehyde levels were significantly higher in the CVH patients than in the control group (p < 0.05), whereas myeloperoxidase activities were significantly lower (p < 0.001). There was no statistically significant difference between nitrotyrosine levels of the patients and the controls (p > 0.05). Additionally, no significant correlation was shown between these markers and viral load, necro-inflammation and fibrosis of the liver in chronic viral hepatitis patients.
Conclusion. The data from this study demonstrate that there is a disturbance in oxidative balance in patients with chronic viral hepatitis, but this imbalance was not correlated with viral load, necro-inflammatory activity or fibrosis of the liver.

Streszczenie

Wprowadzenie. Stres oksydacyjny jest jednym z potencjalnych mechanizmów biochemicznych w patogenezie przewlekłego wirusowego zapalenia wątroby.
Cel pracy. Określenie poziomu stresu oksydacyjnego w dużej grupie chorych na przewlekłe wirusowe zapalenie wątroby (CVH), którzy nie otrzymali leczenia przeciwwirusowego oraz ocena relacji między tymi parametrami i wiremią, stopniem włóknienia i martwiczego zapalenia wątroby.
Materiał i metody. 200 chorych na CVH i 107 zdrowych osób włączono do badania. Ustalono stężenie aldehydu dimalonowego, mieloperoksydazy i nitrotyrozyny.
Wyniki. Stężenie aldehydu dimalonowego było znacząco większe u pacjentów chorych na CVH niż w grupie kontrolnej (p < 0,05), a aktywność mieloperoksydazy była istotnie mniejsza (p < 0,001). Nie stwierdzono statystycznie istotnej różnicy między stężeniem nitrotyrozyny w grupie badanej i kontrolnej (p > 0,05). Nie wykazano także istotnej korelacji między tymi znacznikami a wiremią, martwiczym zapaleniem wątroby i włóknieniem wątroby u chorych na przewlekłe wirusowe zapalenie wątroby.
Wnioski. To badanie pokazuje, że równowaga oksydacyjna u pacjentów z przewlekłym wirusowym zapaleniem wątroby jest zaburzona, ale ten brak równowagi nie jest skorelowany z wiremią, martwiczym zapaleniem wątroby ani włóknieniem wątroby.

Key words

chronic viral hepatitis, malondialdehyde, myeloperoxidase, nitrotyrosine

Słowa kluczowe

przewlekłe wirusowe zapalenie wątroby, aldehyd dimalonowy, mieloperoksydaza, nitrotyrozyna

References (30)

  1. Jain KS, Pemberton WP, Smith A: Oxidative stress in chronic hepatitis C: not just a feature of late stage disease. J Hepatol 2002, 36, 805–811.
  2. Yadav D, Hertan H, Schweitzer P, Norkus P, Pitchumoni: Serum and liver micronutrient antioxidants and serum oxidative stress in patients with chronic hepatitis C. Am J Gasteronterol 2002, 97, 2634–2639.
  3. Jaeschke H: Reactive oxygen and mechanisms of inflammatory liver injury. J Gastroenterol Hepatol 2000, 15, 718–724.
  4. Garcia-Monzon C, Majano LP, Zabia I: Intrahepatic accumulation of nitrotyrosine in chronic viral hepatitis is associated with histological severity of liver disease. J Hepatol 2000, 32, 331–338.
  5. Liu MC, Yasuda S, Idell S: Sulfation of nitrotyrosine: Biochemistry and Functional Implications. IUBMB Life 2007, 59, 622–627.
  6. Arnhold J: Properties, functions, and secretion of human myeloperoxidase. Biochemistry (Mosc) 2004, 69, 4–9.
  7. Gutteridge JM, Halliwell B: The measurement and mechanism of lipid peroxidation in biological systems. Trends Biochem Sci 1989, 15, 129–135.
  8. Zelzer S, Khoschsorur GA, Stettin M, Weihrauch G, Truschnig-Wilders M: Determination of myeloperoxidase in EDTA plasma: Comparison of an enzyme-linked immunosorbent assay with a chemiluminescent automated immunoassay. Clin Chim Acta 2009, 406, 62–65.
  9. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN: Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22, 696–699.
  10. Namıduru ES, Namıduru M, Tarakçıoğlu M, Toy A: Antioxidant defense in patients with chronic hepatitis B and C type. Clin Lab 2010, 56, 207–213.
  11. Fujita N, Horiike S, Sugimoto R, Hideaki T, Iwasa M: Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients. Free Radic Biol Med 2007, 42, 353–362.
  12. Yeşilova Z, Yaman H, Öktenli Ç, Özcan A, Uygun A: Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. Am J Gasteroentorol 2005, 100, 850–855.
  13. Mutlu-Turkoglu U, Ademoglu E, Turkoglu S: The effect of interferon-α on serum lipid peroxidation and total thiol content in patients with chronic active hepatitis-C. Res Commun Mol Pathol Pharmacol 1997, 96, 357–361.
  14. Abakumov GZ, Novitskii GK, Legon’kova LF: The role of lipid peroxidation in the pathogenesis of viral hepatitis. Vopr Med Him 1988, 34, 30–32.
  15. Müller G, Rahfeld B, Jannasch M: Malondialdehyde concentration in blood of patients with liver diseases. Gesamte Inn Med 1992, 47, 263–265.
  16. Demirdag K, Yilmaz S, Ozdarendeli A, Ozden M, Kalkan A, Kilic SS: Levels of plasma malondialdehyde and erythrocyte antioxidant enzyme activities in patients with chronic hepatitis B. Hepato-gastroenterology 2003, 50, 766–770.
  17. Valgimigli L, Valgimigli M, Gaiani S, Pedulli GF, Bolondi L: Measurement of oxidative stress in human liver by EPR spin-probe technique. Free Radical Res 2000, 33, 167–178.
  18. Kılıc N, Kalkan A, Ozden M, Denk A: HbeAg pozitif kronik hepatit B olgularında serum malondialdehit düzeyinin karaciğer histopatolojisi ve interferon tedavisi ile ilişkisi. İnfeksiyon Dergisi 2005, 19, 5–9.
  19. Kaya S, Sütçü R, Sesli E: Hepatit B virüs ile infekte hastalarda viral yük ile lipid peroksidasyonu ve antioksidan enzimler arasındaki ilişki. Türk Klinik Biyokimya Dergisi. 2006, 4, 77–82.
  20. Bekheet IW, Madkour ME, Ghaffar NA, Nosseir MMF, Moussa MM, Ibraheim RA, Ateya MA: The Role of Myeloperoxidase in Hepatitis C Virus Infection and Associated Liver Cirrhosis. Open Trop Med J 2009, 2, 1–7.
  21. Babior BM: NADPH oxidase. Curr Opin Immunol 2004, 16, 42–47.
  22. Segal AW, Abo A: The biochemical basis of the NADPH oxidase of phagocytes. Trends Biochem Sci 1993, 18, 43–47.
  23. Kothari N, Keshari RS, Bogra J, Kohli M, Abbas H, Malik A et al.: Increased myeloperoxidase enzyme activity in plasma is an indicator of inflammation and onset of sepsis. J Crit Care 2010, 29, 1–7.
  24. Cuzzocrea S, Costantino G, Mazzon E, Caputi AP: Beneficial effects of Mn(III)tetrakis (4-benzoic acid) porphyrin (MnTBAP), a superoxide dismutase mimetic, in zymosan-induced shock. Crit Care Med 1999, 27, 1524– 1532.
  25. Van der Vliet A, Nguyen MN, Shigenaga MK, Eiserich JP, Marelich GP, Cross CE: Myeloperoxidase and protein oxidation in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2000, 279, 537–546.
  26. Baldus S, Eiserich JP, Brennan ML, Jackson RM, Alexander CB, Freeman BA: Free Rad Biol Med 2002, 33, 1010–1019.
  27. Dikici I, Mehmetoglu I, Dikici N, Bitirgen M, Kurban S: Investigation of oxidative stress and some antioxidants in patients with acute and chronic viral hepatitis B and the effect of interferon-alpha treatment. Clin Biochem 2005, 38(12), 1141–1144.
  28. Togashi H, Ohno S, Matsuo T: Interferon-gamma, tumor necrosis factor-alpha, and interleukin 1-beta suppress the replication of hepatitis B virus through oxidative stress. Res Commun Mol Pathol Pharmacol 2000, 107, 407– 417.
  29. Pietrangelo A: Iron, oxidative stress and liver fibrogenesis. J Hepatol 1998, 28, 8–13.
  30. Fujita N, Sugimoto R, Ma N, Tanaka H, Iwasa M, Kobayashi Y et al.: Comparison of hepatic oxidative DNA damage in patients with chronic hepatitis B and C. J Viral Hepatol 2008, 15, 498–507.
© Wroclaw Medical University